- 1 Title: Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in
- 2 seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine
- 3 administration
- 4 **Authors:** Francisco Belda^{1*}, Oscar Mora¹, Monica Lopez-Martinez², Nerea Torres², Ana
- 5 Vivanco², Silvia Marfil³, Edwards Pradenas³, Marta Massanella^{3,4}, Julià Blanco^{3,4,5},
- 6 Rebecca Christie⁶, Michael Crowley⁶
- 7 Affiliations: ¹ Research and Development, Bio Supplies Division, Grifols, 08174 Sant
- 8 Cugat del Vallès (Barcelona), Spain
- 9 ² R&D Department, Progenika Biopharma, A Grifols Company, Ibaizabal Bidea, Edificio
- 10 504, Parque Tecnológico de Bizkaia, 48160 Derio, Bizkaia, Spain
- ³IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can
- 12 Ruti Campus, UAB, 08916, Badalona, Catalonia, Spain
- 13 ⁴Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC,
- 14 Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid, Spain
- ⁵University of Vic–Central University of Catalonia (UVic-UCC), 08500, Vic, Catalonia,
- 16 Spain
- 17 ⁶Access Biologicals, Vista, CA 92081, USA
- 18 *Corresponding Author: Dr. Francisco Belda
- 19 Grifols
- 20 Parc Empresarial Can Sant Joan
- 21 Av. De la Generalitat, 152-158
- 22 08174 Sant Cugat del Vallès (Barcelona), Spain
- 23 Telephone: 34 935 710 313; Email: paco.belda@grifols.com
- 24 No Runnips Title por Remonstration of non title differences piloste Ser San Sa Sa Vianot be used to guide clinical practice.

25 Abstract:

- 26 Seroconversion panels were collected before and after vaccination with three COVID-19
- 27 vaccines: two mRNA vaccines (mRNA-1273 and BNT-162b2) and one adenovirus vector vaccine
- 28 (Ad26.COV2.S). The panels were tested for antibody activity by chemiluminescent
- immunoassay, ELISA and one was tested in a pseudovirus neutralization assay.
- 30 Participants positive for anti-SARS-CoV-2 antibodies before vaccination (18.6%) had a higher
- 31 response to the first vaccine dose than participants who tested negative. For two-dose
- 32 vaccines, older participants showed a lower response to the first dose than younger
- 33 participants. All participants showed positive antibody responses after the second vaccine. For
- 34 the adenovirus vector vaccine, two participants did not generate antibody responses two
- 35 weeks and two months after vaccination. Three participants were negative at two weeks but
- 36 positive at two months. Pseudovirus neutralization showed good correlation with antibody
- 37 activity (correlation coefficient =0.78, p<0.0001). Antibody responses in participants over 45
- 38 years old tended to be less robust.
- 39

40 Keywords:

- 41 SARS-CoV-2, neutralizing antibodies, binding antibodies, seroconversion panels, vaccines,
- 42 mRNA-1273, BNT-162b2, Ad26.COV2.S.

43 Introduction

| 44 | Since the start of the SARS-CoV-2 pandemic, nearly 30 pharmaceutical |
|----|--|
| 45 | companies, research institutes and academic laboratories worldwide have been |
| 46 | working toward the development of effective vaccines against COVID-19. These efforts |
| 47 | have taken various approaches including mRNA, DNA, protein subunits, and |
| 48 | attenuated or non-replicating viruses. [1] Among the vaccines utilizing mRNA and |
| 49 | nanotechnology, mRNA-1273 (Moderna) and BNT-162b2 (Pfizer/BioNTech) are the |
| 50 | most advanced. |
| 51 | Within one year of the emergence of the SARS-CoV-2 virus, these two novel |
| 52 | and effective mRNA vaccines became available under emergency use authorization |
| 53 | (EUA) by the US Food and Drug Administration (FDA). The BNT162b2 vaccine contains |
| 54 | 30 μg of SARS-CoV-2 full-length spike (pre-fusion conformation) mRNA administered as |
| 55 | two doses three weeks apart. The mRNA-1273 vaccine 100 μg of pre-fusion-stabilized |
| 56 | spike glycoprotein mRNA given as two doses four weeks apart. [2] |
| 57 | The BNT-162B2 vaccine (Comirnaty [®] , BioNTech, Mainz, Germany/Pfizer, New York, |
| 58 | NY, USA) was first utilized under an EUA beginning December 11, 2020 [3] and became |
| 59 | the first COVID-19 vaccine approved by the FDA on August 23, 2021. It was approved |
| 60 | for the prevention of COVID-19 in individuals 16 years of age and older. In addition, the |
| 61 | BNT-162B2 vaccine is available for use under an emergency use authorization (EUA) for |
| 62 | children ages 12 to 15 years and as a third booster dose in immunocompromised |
| 63 | individuals, people over 65, individuals between 16 and 64 who are at high risk of |
| 64 | severe COVID-19 and person with high environmental exposure to SARS-CoV-2 which |
| 65 | puts them at risk for severe COVID-19. [4] |

| 66 | The FDA issued an EUA for the mRNA-1273 vaccine for the prevention of |
|----|---|
| 67 | COVID-19 in individuals over 18 years of age on December 18, 2020. As with the EUA |
| 68 | for BNT-162b2, the EUA for mRNA-1273 was amended in August 2021 to allow the |
| 69 | administration of an additional dose to certain immunocompromised individuals. [5] |
| 70 | The Ad26.COV2.S vaccine (Janssen/Johnson & Johnson, Beerse, Belgium) uses a |
| 71 | recombinant, replication-incompetent human adenovirus type 26 vector. This vector |
| 72 | encodes for a full SARS-CoV-2 spike protein in a stabilized pre-fusion conformation. A |
| 73 | single dose of Ad26.COV2.S protected vaccinated individuals against symptomatic and |
| 74 | asymptomatic SARS-CoV-2 infection. For those who did get infected, the vaccine was |
| 75 | effective in preventing severe disease including hospitalization and death. [6] |
| 76 | Infection with SARS-CoV-2 or vaccination with an effective vaccine initiates an |
| 77 | immune response with includes the production of antibodies that bind to viral |
| 78 | proteins, i.e., binding antibodies.[7] Not all binding antibodies can block cellular |
| 79 | infiltration and/or replication by the SARS-CoV-2 virus. The subpopulation of |
| 80 | antibodies that can block these processes are called neutralizing antibodies (NAbs). It |
| 81 | is unknown when in the course of infection or after vaccination NAbs are produced or |
| 82 | if they are produced from the onset of antibody formation. While most individuals |
| 83 | produce binding antibodies in response to SARS-CoV-2 infection, not all will develop |
| 84 | NAbs to SARS-CoV-2.[8] |
| 85 | Most SARS-CoV-2 infections induce a response in the adaptive immune system. |
| 86 | [9] NAbs that prevent the virus from binding to the host-cell receptor, angiotensin |

87 converting enzyme 2 (ACE2) are essential for this immune response. NAbs target the

receptor binding domain (RBD) of the viral spike protein and thereby inhibit ACE2

| 89 | binding. [10, 11] These NAbs may be of therapeutic value through treatments such as |
|----|--|
| 90 | convalescent plasma [12], and hyperimmune globulins. [13] In addition, they can serve |
| 91 | as structural templates for vaccine development. Consequently, there is a need for |
| 92 | assays that reliably and efficiently identify the most potent NAbs. The gold standard to |
| 93 | detect NAbs is a virus neutralization test conducted on live cells which can be |
| 94 | performed with live virus or psuedoviruses. [14] The level of neutralizing antibodies |
| 95 | that confers immunity to infection/reinfection with SARS-CoV-2 has yet to be |
| 96 | elucidated. [15] |

Seroconversion panels are a series of blood samples collected before and after 97 the development of antibodies in response to viral infection or vaccination. These 98 99 panels can be useful in the development of antibody assays, determination of the 100 window period of detection (the period between infection and the appearance of antibodies), and the development (validation) and manufacture (quality control) of 101 102 commercial antibody tests. Reliable detection of viral exposure and vaccine 103 effectiveness is a critical step in gaining control of the current COVID-19 pandemic and allowing the general population to return to normal ways of life. The panels can also 104 105 be a source of well-defined neutralizing antibodies (before and after vaccination) that 106 can be useful in investigating their effectiveness against new SARS-CoV-2 variants. The studies in this paper describe the characterization of seroconversion panels from 107 108 donors vaccinated for COVID-19 with the three vaccines currently available in the US: BNT-162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S 109 (Janssen/Johnson & Johnson). 110

111 Materials and Methods

112 Seroconversion Panel Collection

| 113 | The seroconversion panels described in this paper were derived from samples |
|-----|--|
| 114 | collected at a hospital from volunteer donors. The donors provided informed consent |
| 115 | and their samples were collected under an approved IRB protocol ([1149706-4] |
| 116 | Diagnostic QC and Pre-Clinical Sample Collection Project: Ballad Health System |
| 117 | Institutional Review Board (IRB #00003204), Johnson City, TN, USA). These studies |
| 118 | were conducted in compliance with all applicable regulatory guidelines. The |
| 119 | seroconversion panels were comprised of serum samples collected before and after |
| 120 | administration of the COVID-19 vaccines. This study characterizes the appearance of |
| 121 | anti-SARS-CoV-2 antibodies after vaccine administration. |
| 122 | Four seroconversion panels were analyzed in this study: one mRNA-1273 |
| 123 | (Moderna) n = 15 donors; two BNT-162b2 (Pfizer/BioNTech) n = 15 donors for each |
| 124 | panel; and one Ad26.COV2.S (Janssen/Johnson & Johnson) n= 14 donors. For mRNA- |
| 125 | based vaccines (mRNA-1273 and BNT-162b2) panels, samples were collected prior to |
| 126 | the first vaccination (objective target \leq 2 days: sample 1), prior to the second |
| 127 | vaccination (objective target \leq 2 days: sample 2), and after the second vaccination |
| 128 | (objective target 13-15 days; sample 3). For Ad26.COV2.S, samples were collected on |
| 129 | vaccination day (prior to the injection: sample 1), two weeks after vaccination (14 |
| 130 | days: sample 2) and 2 months after vaccination (59-62 days: sample 3). Samples were |
| 131 | collected as plasma (in the presence of potassium EDTA) and/ or serum (in serum |
| 132 | separating tubes). |

As previously described [16], the mRNA-1273 panel was made up of undiluted,
unpreserved serum samples collected from 15 participants between 22 December
2020 and 25 February 2021. The donors were health adults (21-76 years old) who
received the prescribed course of mRNA-1273 vaccines (two injections of 100 μg objective target 28 days apart). There were 10 female and 5 male donors, and all were
white/Caucasian.

The two BNT-162b2 panels were collected at different times. The first panel 139 140 (BNT-162b2 Panel 1) was collected between 19 February 2021 and 23 April 2021. The second panel (BNT-162b2 Panel 2) was collected between 25 May 2021 and 24 141 September 2021. The BNT-162b2 panels were either undiluted, unpreserved serum or 142 143 EDTA-treated plasma collected from 15 donors each. These donors were healthy adults 144 36-70 years old for the first panel and 29 to 67 years old for the second panel. The 145 participants for both panels received the approved vaccination regimen (two injections of BNT-162b2 30 µg – objective target 21 days apart). There were 7 female and 8 male 146 147 donors in panel 1 and 9 female and 6 male donors in panel 2. All the donors were white/Caucasian. 148

The Ad26.COV2.S panel was undiluted, unpreserved serum collected from 14 donors between 7 March 2021 and 24 September 2021. These donors were between 31 and 64 years of age. There were equal numbers (n=7) of female and male donors and all were white/Caucasian. These donors received the approved regimen of a single injection (0.5 mL) of the Ad26.COV2.S vaccine.

All samples were stored at -20°C until analyzed. Prior to analysis, samples were thawed at room temperature and mixed by inversion.

156 CLIA and ELISA Assays

| 157 The samples in the seloconversion panels were tested for the presence of anti-SARS | 157 | The samples in the se | proconversion panels we | ere tested for the | presence of anti-SARS- |
|--|-----|-----------------------|-------------------------|--------------------|------------------------|
|--|-----|-----------------------|-------------------------|--------------------|------------------------|

- 158 CoV-2 antibodies using chemiluminescent immunoassays (CLIA: Liaison SARS-CoV-2 IgG assay,
- 159 Diasorin, Inc., Saluggia, Italy; EUA approved) and enzyme-linked immunosorbent assays (ELISA:
- 160 Progenika anti-SARS-CoV-2 lgG Kit, Progenika Biopharma, Derio, Bizkaia, Spain; CE-IVD certified
- 161 immunoassay). These assays were performed following the directions provided by the
- 162 manufacturers. The Diasorin assay utilizes antigens to the S1 and S2 spike protein IgG while the
- 163 Progenika assay utilizes only antigens to S1 IgG. The specific sequences antigens are not
- 164 disclosed. Since the assays were developed independently, they are assumed to be non-
- 165 identical.
- 166 A kappa correlation (JMP software 16.0) statistic test was performed to compare the
- 167 qualitative values between CLIA and ELISA assays.
- 168 Neutralizing Antibody Determination
- 169 Cell line
- 170 HEK293T cells (presumably of female origin) overexpressing wild-type human ACE-2
- 171 (Integral Molecular, USA) were used as target for SARS-CoV-2 spike expressing pseudovirus
- 172 infection. Cells were maintained in T75 flasks with Dulbecco's Modified Eagle's Medium

173 (DMEM) supplemented with 10% fetal bovine serum and 1µg/mL puromycin).

174 **Pseudovirus generation**

175 Pseudoviruses (HIV reporter) expressing the SARS-CoV-2 S protein and luciferase were

176 constructed using the defective HIV plasmid, pNL4-3.Luc.R-.E-. The plasmid was obtained from

- the NIH AIDS Reagent Program. [17] Expi293F cells were transfected using ExpiFectamine293
- 178 Reagent (Thermo Fisher Scientific, Waltham, MA, USA) with pNL4-3.Luc.R-.E- and SARS-CoV-
- 179 2.SctΔ19 (Wuhan, G614 or B.1.1.7); at an 8:1 ratio, respectively. Control pseudoviruses were
- 180 generated by replacing the S protein expression plasmid with a vesicular stomatitis virus (VSV)-
- 181 G protein expression plasmid as previously reported. [18] Supernatants were harvested 48

hours after transfection, filtered at 0.45 μm, frozen, and titrated on HEK293T cells

183 overexpressing wild-type human ACE-2.

184 Neutralization assays

- Neutralization assays were performed in duplicate. Briefly, 200X the median tissue
 culture infectious dose (TCID50) of pseudovirus was preincubated with three-fold serial
 dilutions (1/60–1/14,580) of heat-inactivated plasma samples in Nunc 96-well cell culture
 plates (Thermo Fisher Scientific) for 1 h at 37°C. Then 2 x 10⁴ HEK293T/hACE2 cells treated
 with DEAE-Dextran (Sigma-Aldrich, St. Louis, MO, USA) were added. Results were read after 48
 h using an EnSight Multimode Plate Reader and BriteLite Plus Luciferase reagent (Perkin Elmer,
 Waltham, MA, USA).
- 192The results were normalized and the ID50 (the reciprocal dilution inhibiting 50% of the

193 infection) was calculated by plotting the log of plasma dilution versus response and fitting to a

194 4-parameter equation in Prism 8.4.3 (GraphPad Software, San Diego, CA, USA). This

neutralization assay has been previously validated in a large subset of samples. [7]

196 **RESULTS**

197 mRNA-1273 (Moderna) seroconversion panel

198 As previously described [16], the pre-vaccination samples in the mRNA-1273 panel 199 showed positive values for two participants suggesting that they had been previously infected 200 with SARS-CoV-2 (participants 5 and 15). The post-vaccination samples collected from these 201 participants after the first dose showed the largest antibody responses in the panel. After the 202 first dose of mRNA-1273, samples from 13 of the 15 participants showed positive antibody 203 response by CLIA and 14 of 15 by ELISA. The two participants who tested negative after the first dose of vaccine were the oldest participants in the panel (> 70 years old: participants 3 204 205 and 4). After the second dose, samples for all 15 of the participants were positive for anti-206 SARS-CoV-2 antibodies (in both assays). Overall, there was good agreement between the

207 results of the CLIA and ELISA assays (Kappa coefficient = 0.947). The value of the equivocal

208 range was eliminated to perform this statistical test.

The post-vaccination second dose samples from the mRNA-1273 panel were tested for neutralizing antibodies. The samples from all participants were positive for neutralizing antibodies (Figure 1). When the neutralizing antibody results were compared with the ELISA antibody detection results, a positive correlation was observed in both analyses (Correlation

213 coefficient=0.78 and p-value<0.0001).

214 BNT-162b2 (Pfizer/BioNTech) seroconversion panels

Testing (CLIA) of the pre-vaccination samples in BNT-162b2 Panel 1 gave the following results (Figure 2; first point): 12 negative and 3 positive results (participants 2, 5 and 15). The detection of anti-SARS-CoV-2 antibodies in these three participants indicates that they were infected with the virus prior to collection of the samples.

219 Sample collected after the first vaccine injection showed 14 positive and 1 negative

results (Figure 2; second point). The largest antibody responses were detected in the three

participants (2, 5 and 15) who had detectable antibodies in their pre-vaccination samples. The

sample from participant 12 also showed a high antibody response to the first vaccine injection.

223 The pre-vaccination sample from this participant was close to the cutoff value for positivity.

224 The single negative sample collected after the first vaccine dose was in one of the older

225 participants (participant 1; 55-60 years old).

Samples collected after the second vaccine injection were positive in all 15 participants
(Figure 2; third point). Lower antibody responses were seen in four participants (3, 4, 7 and 14)

228 compared to the rest of the participants. These participants were between 55 and 80 years

old. The sample from participant 7 (60-65 years old) showed a lower level of antibody activity

after the second vaccine dose that that seen after the first vaccine dose.

Results from CLIA testing of a second BNT-162b2 seroconversion panel (BNT-162b2
Panel 2) showed ten negative and 5 positive anti-SARS-CoV-2 antibody responses in the pre-

vaccination samples (Figure 3; first point – participants 4, 8, 9, 10 and 15). As previously noted,

the presence of anti-SARS-CoV-2 IgG in pre-vaccination samples indicates infection with SARS-

235 CoV-2 prior to collection of the samples.

- 236 The samples in this panel collected after the first injection of the BNT-162b2 vaccine
- showed 13 positive and 2 negative results (Figure 3; second point). As with Panel 1, the

238 greatest antibody responses were detected in the five participants that had detectable anti-

- 239 SARS-CoV-2 antibodies in their pre-vaccination samples (participants 4, 8, 9, 10 and 15). Two
- 240 participants had negative antibody responses after the first vaccine injection (participants 7
- and 12). These participants were 45-50 and 25-30 years old.

242 The sample collected after the second BNT-162b2 vaccine injection were positive for

all 15 participants (Figure 3; third point). The lowest activity was seen in participant 12 (25-30

244 years old) 16 AU/mL just above the cutoff value of 15 AU/mL. This participant (12) was one of

the two participants that tested negative after the first vaccination. The other participants with

low antibody responses (1, 5 and 7) were 45-60 years old.

247 Ad26.COV2.S (Janssen/Johnson & Johnson) seroconversion panel

Testing of the pre-vaccination samples for the Ad26.COV2.S panel showed 13 negative and 1 positive anti-SARS-CoV-2 antibody responses (Figure 4; first point). The one positive sample indicates a previous SARS-CoV-2 infection in this participant (11) prior to the collection of the sample.

The samples collected two weeks after the single-dose vaccination showed eight positive and 6 negative antibody responses (Figure 4; second point). Samples from 12 participants showed positive responses two months after vaccination (Figure 4; third point). Two participants (3 and 6) showed negative antibody responses after two weeks and two months. These participants were 40-45 and 60-65 years old. The three participants that showed a negative antibody response at two weeks but a positive response at two months

258 were 30-35 (n=1) and 60-65 (n=2) years old.

259 Discussion

| 260 | Four seroconversion panels have been created by collecting serum or plasma samples |
|-----|---|
| 261 | from participants before and after COVID-19 vaccination. Three of the panels were drawn from |
| 262 | participants who were administered one of the two-dose mRNA-based vaccines (mRNA-1273 - |
| 263 | one panel and BNT-162b2 – two panels) and one panel from participants given a single dose of |
| 264 | the replication-incompetent adenovirus-based vaccine (Ad26.COV2.S). These panels were |
| 265 | tested using CLIA and ELISA technologies. Comparison of the CLIA and ELISA results for the |
| 266 | mRNA-1273 panel showed good agreement between these assays. [16] |
| 267 | In addition, neutralization assays were conducted in this study and showed |
| 268 | congruence between the neutralization assay and the CLIA. Neutralizing activity that blocks |
| 269 | viral entry into cell has been shown to be responsible for antibody-mediated prevention of |
| 270 | coronavirus infection. [19] Neutralizing anti-SARS-CoV-2 antibodies have been shown to mainly |
| 271 | target the receptor-binding domains on the S1 region of the spike protein. [20] When |
| 272 | immunoassay results correlate with neutralization assays, as in this study, the simpler, less |
| 273 | labor-intensive immunoassays may be a useful initial indirect screen for antibody |
| 274 | neutralization activity. A similar correlation between immunoassay and neutralization results |
| 275 | has been seen in other studies. [21, 22] |
| 276 | The results from all the seroconversion panels illustrate several important points |
| 277 | regarding antibody responses to vaccination against COVID-19: 1) There is a small but |
| 278 | significant fraction (18.6%) of the general population (as measured by the participants in this |
| 279 | study) that have been infected with SARS-CoV-2 and have antibodies to the virus prior to |
| 280 | vaccination; 2) For the mRNA-based vaccines, the second dose raised anti-SARS-CoV-2 |
| 281 | antibody levels in participants without a previous SARS-CoV-2 infection to the same levels as |
| 282 | those participants who had been infected with SARS-CoV-2 and had antibodies prior to |
| 283 | vaccination; 3) Antibody responses tended to be less robust in the participants over 45 years |
| 284 | old. |

- 285 Acknowledgements: Michael K. James, Ph.D. is acknowledged for medical writing and
- 286 Jordi Bozzo, Ph.D., CMPP for editorial assistance.
- 287

288 <u>References</u>

- 289 1. Noor, R., Developmental Status of the Potential Vaccines for the Mitigation of the
- 290 COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and
- 291 *Moderna mRNA Vaccines*. Curr Clin Microbiol Rep, 2021: p. 1-8.
- 292 2. Montoya, J.G., et al., *Differences in IgG antibody responses following BNT162b2 and*
- 293 *mRNA-1273 vaccines.* bioRxiv, 2021.
- 294 3. *Emergency Use Authorization (EUA) for an unapproved product review memorandum:*
- 295 Pfizer-BioNTech COVID-19 Vaccine/BNT-162b2. 2020 12 Oct 2021]; Available from:
- 296 https://www.fda.gov/media/144416/download.
- 297 4. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. 2021 14 December 2021 16
- 298 December 2021]; Available from: https://www.fda.gov/emergency-preparedness-and-
- response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19 vaccine.
- 301 5. Moderna COVID-19 Vaccine. 2021 13 December 2021 16 December 2021]; Available
- 302 from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-
- 303 disease-2019-covid-19/moderna-covid-19-vaccine.
- 304 6. Sadoff, J., et al., Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-
- 305 *19*. N Engl J Med, 2021. **384**(23): p. 2187-2201.
- Trinite, B., et al., SARS-CoV-2 infection elicits a rapid neutralizing antibody response
 that correlates with disease severity. Sci Rep, 2021. 11(1): p. 2608.
- 308 8. Carrillo, J., et al., *Humoral immune responses and neutralizing antibodies against SARS-*
- 309 *CoV-2; implications in pathogenesis and protective immunity.* Biochem Biophys Res

310 Commun, 2021. **538**: p. 187-191.

- 311 9. Garritsen, A., et al., *Two-tiered SARS-CoV-2 seroconversion screening in the*
- 312 Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing
- 313 *antibodies.* Infect Dis (Lond), 2021. **53**(7): p. 498-512.
- 10. Wu, Y., et al., A noncompeting pair of human neutralizing antibodies block COVID-19
- 315 *virus binding to its receptor ACE2.* Science, 2020. **368**(6496): p. 1274-1278.
- 316 11. Zost, S.J., et al., Potently neutralizing and protective human antibodies against SARS-
- 317 *CoV-2.* Nature, 2020. **584**(7821): p. 443-449.
- 318 12. Piechotta, V., et al., *Convalescent plasma or hyperimmune immunoglobulin for people*
- 319 *with COVID-19: a living systematic review.* Cochrane Database Syst Rev, 2021. **5**: p.
- 320 CD013600.
- 321 13. Vandeberg, P., et al., *Production of anti-SARS-CoV-2 hyperimmune globulin from*322 *convalescent plasma*. Tranfusion, 2021: p. 1-5.
- Fiedler, S., et al., Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2
 Binding in Patient Serum. ACS Infect Dis, 2021. 7(8): p. 2362-2369.
- 325 15. Bubonja-Sonje, M., et al., *Diagnostic accuracy of three SARS-CoV2 antibody detection*
- 326 *assays, neutralizing effect and longevity of serum antibodies.* J Virol Methods, 2021.
- 327 **293**: p. 114173.
- 328 16. Belda, F., et al., Seroconversion panels demonstrate anti-SARS-CoV-2 antibody
- 329 *development after administration of the mRNA-1273 vaccine.* medRxiv, 2021.
- 330 17. Connor, R.I., et al., *Vpr is required for efficient replication of human immunodeficiency*
- 331 virus type-1 in mononuclear phagocytes. Virology, 1995. **206**(2): p. 935-44.
- 18. Sanchez-Palomino, S., et al., A cell-to-cell HIV transfer assay identifies humoral
- 333 *responses with broad neutralization activity.* Vaccine, 2011. **29**(32): p. 5250-9.
- Qian, Z., et al., *Identification of the Receptor-Binding Domain of the Spike Glycoprotein*of Human Betacoronavirus HKU1. J Virol, 2015. **89**(17): p. 8816-27.

| 336 | 20. | Ou, X., et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and |
|-----|-----|--|
| 337 | | its immune cross-reactivity with SARS-CoV. Nat Commun, 2020. 11(1): p. 1620. |
| 338 | 21. | Mendrone-Junior, A., et al., Correlation between SARS-COV-2 antibody screening by |
| 339 | | <i>immunoassay and neutralizing antibody testing.</i> Transfusion, 2021. 61 (4): p. 1181- |
| 340 | | 1190. |
| 341 | 22. | Tan, C.W., et al., A SARS-CoV-2 surrogate virus neutralization test based on antibody- |
| 342 | | mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol, 2020. |
| 343 | | 38 (9): p. 1073-1078. |
| 344 | | |

| 346 | Author Contributions: | All authors have | e participated in t | he conception or | [·] design of the |
|-----|-----------------------|------------------|---------------------|------------------|----------------------------|
|-----|-----------------------|------------------|---------------------|------------------|----------------------------|

- 347 work, data collection and critical revision of the article. FB, OM, RC and NC conceived
- 348 the study. FB, OM and MC provided administrative support. RC and MC provided study
- 349 materials (developed the seroconversion panels). FB, OM, MLM, NT AV and RC
- 350 participated in the collection and assembly of data. SF, EP, MM and JB performed the
- 351 neutralization experiments. All authors participated in data analysis and interpretation,
- 352 manuscript writing and gave approval of the final manuscript.

354 Figure Legends

Figure 1. Antibody responses in a seroconversion panel of 15 participants after vaccination
with two doses of the mRNA-1273 SARS-CoV-2 vaccine (Moderna). The column in blue, shows
the results of neutralizing antibody titers expressed in (IC₅₀ Reciprocal Dilution). Responses ≥
250 were considered positive. The column in brown, shows the antibody responses obtained
using an enzyme-linked immunosorbent assay (ELISA). Responses ≥ 1.1 S/CO were considered
positive.

361 Figure 2. Antibody responses in a seroconversion panel of 15 subjects before and after

362 vaccination with two doses of the BNT162b2 SARS-CoV-2 vaccine (Pfizer/BioNTech) -Panel 1.

363 These results were obtained using a chemiluminescent immunoassay and are expressed as

arbitrary units/mL (AU/mL). Responses \geq 15.0 units were considered positive. The first point

365 shows results from samples collected prior to the first vaccination. The second point shows the

366 results from samples collected after the first vaccination and prior to the second vaccination.

367 The third point shows the results from samples collected after the second vaccination. The

368 dashed lines correspond to the convalescent participants, while the solid lines correspond to

the naïve participants.

370 Figure 3. Antibody responses in a seroconversion panel of 15 subjects before and after 371 vaccination with two doses of the BNT162b2 SARS-CoV-2 vaccine (Pfizer/BioNTech) – Panel 2. 372 These results were obtained using a chemiluminescent immunoassay and are expressed as 373 arbitrary units/mL (AU/mL). Responses \geq 15.0 units were considered positive. The first point 374 shows results from samples collected prior to the first vaccination. The second point shows the 375 results from samples collected after the first vaccination and prior to the second vaccination. 376 The third point shows the results from samples collected after the second vaccination. The 377 dashed lines correspond to the convalescent participants, while the solid lines correspond to the 378 naïve participants.

379 Figure 4: Antibody responses in a seroconversion panel of 14 subjects before vaccination with 380 one dose of the Ad26.CoV2.S SARS-CoV-2 vaccine (Janssen/Johnson & Johnson). These results 381 were obtained using a chemiluminescent immunoassay are expressed as arbitrary units/mL 382 (AU/mL). Responses ≥ 15.0 units were considered positive. The first point shows results from 383 samples collected prior the vaccination. The second point shows the results from samples 384 collected two weeks after the vaccination. The third point shows the results from samples 385 collected two months after vaccination The dashed lines correspond to the convalescent participants, while the solid lines correspond to the naïve participants. 386

Figure 1.



389

391 Figure 2.



394 Figure 3.



397 Figure 4.

